ReviewDiagnostics (Basel, Switzerland)2023
Modern Methods of Diagnostics and Treatment of Neurodegenerative Diseases and Depression.
Review in Diagnostics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- Effects of a dual intervention (motor and virtual reality-based cognitive) on cognition in patients with mild cognitive impairment: a single-blind, randomized controlled trial.Journal of neuroengineering and rehabilitation · 2024Trial
- Self-Assembled EGCG@Zn Fluorescent Nanocomplexes for Sensitive Detection of Amyloid-βJournal of fluorescence · 2026Article
- The neuroimmune system and cognition.Nature immunology · 2026Review
- Clinical translation of fluid, imaging, and digital biomarkers for Alzheimer's disease.Alzheimer's research & therapy · 2026Review
- Smart Nanomedicines for Neurodegenerative Diseases: Empowering New Therapies with Molecular Imaging and Artificial Intelligence.Molecular diagnosis & therapy · 2026Review
- Coenzyme QMetabolic brain disease · 2025Article
- The usefulness of microbiome profiling for geriatric patients with neuropsychiatric conditions: a scoping review.Translational psychiatry · 2025Article
- A critical review on neurodegenerative biomarker diagnostics: where is the field heading to?Analytical and bioanalytical chemistry · 2025Review
- A new parallel-path ConvMixer neural network for predicting neurodegenerative diseases from gait analysis.Medical & biological engineering & computing · 2025Article
- Natural Neuroinflammatory Modulators: Therapeutic Potential of Fungi-Derived Compounds in Selected Neurodegenerative Diseases.Molecules (Basel, Switzerland) · 2025Review
- Public hesitancy for AI-based detection of neurodegenerative diseases in France.Scientific reports · 2025Article
- Exploring Non-Pharmacologic Adjunctive Therapies for Patients with Neurodegenerative Diseases.Medicina (Kaunas, Lithuania) · 2025Review
- Exosomes as Biomarkers and Therapeutic Agents in Neurodegenerative Diseases: Current Insights and Future Directions.Molecular neurobiology · 2025Review
- Longitudinal description of health-related quality of life and depressive symptoms in polyQ spinocerebellar ataxia patients.Journal of neurology · 2025Article
- Building healthcare capacity for neurodegenerative disease management in Nigeria: Challenges and opportunities.Journal of public health research · 2025Article
- Extracellular vesicles: new horizons in neurodegeneration.EBioMedicine · 2025Review
- Convolutional Neural Network for Depression and Schizophrenia Detection.Diagnostics (Basel, Switzerland) · 2025Article
- Viruses and neurodegeneration: a growing concern.Journal of translational medicine · 2025Review
- From Skin and Gut to the Brain: The Infectious Journey of the Human Commensal Fungus Malassezia and Its Neurological Consequences.Molecular neurobiology · 2025Review
- The potential of exosomes in regenerative medicine and in the diagnosis and therapies of neurodegenerative diseases and cancer.Frontiers in medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
This paper discusses the promising areas of research into machine learning applications for the prevention and correction of neurodegenerative and depressive disorders. These two groups of disorders are among the leading causes of decline in the quality of life in the world when estimated using disability-adjusted years. Despite decades of research, the development of new approaches for the assessment (especially pre-clinical) and correction of neurodegenerative diseases and depressive disorders remains among the priority areas of research in neurophysiology, psychology, genetics, and interdisciplinary medicine. Contemporary machine learning technologies and medical data infrastructure create new research opportunities. However, reaching a consensus on the application of new machine learning methods and their integration with the existing standards of care and assessment is still a challenge to overcome before the innovations could be widely introduced to clinics. The research on the development of clinical predictions and classification algorithms contributes towards creating a unified approach to the use of growing clinical data. This unified approach should integrate the requirements of medical professionals, researchers, and governmental regulators. In the current paper, the current state of research into neurodegenerative and depressive disorders is presented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.